Market Cap 1.30B
Revenue (ttm) 8.33M
Net Income (ttm) -89.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,072.03%
Debt to Equity Ratio 0.17
Volume 2,084,980
Avg Vol 6,968,804
Day's Range N/A - N/A
Shares Out 272.80M
Stochastic %K 30%
Beta 0.99
Analysts Strong Sell
Price Target $9.77

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 214 612 0000
Address:
3000 Pegasus Park Drive, Suite 1430, Dallas, United States
Dark_Horse_Investments
Dark_Horse_Investments Oct. 27 at 6:57 PM
$TSHA choppy seesaw reaction the last ~two weeks ... Do we think this will end the year above $6 ? THX & good luck
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 26 at 5:16 PM
Nice to see RA Capital long 7m shares of $RNA. A cool $1/2b that needs re-investing tomorrow thanks to $NVS. They are some lucky investors - or . *are they the actual people who facilitate value creation*? https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline $IFRX $CDTX $TSHA
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:43 PM
Raymond James has updated their rating for Taysha Gene Therapies ( $TSHA ) to Strong Buy with a price target of 13.
1 · Reply
King_of_Bio
King_of_Bio Oct. 21 at 3:22 PM
$TSHA She's headed for the next leg up!
1 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 10:40 PM
$ABAT what a comeback 💪🤑💰💰💰💰 RVP is my next one 🚨🚨🚨 Here’s why👇 $BYND $TSHA what an AH
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
biotech
biotech Oct. 20 at 5:37 PM
1 · Reply
quickaspeter
quickaspeter Oct. 19 at 11:30 PM
$TSHA “Taysha Gene Therapies regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.” https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-valuation-perspectives-after-rega
0 · Reply
Mighty_Fire_5931
Mighty_Fire_5931 Oct. 19 at 10:11 PM
$TSHA Perfect bounce off support, adding here
0 · Reply
Dkll303
Dkll303 Oct. 18 at 1:04 PM
$QURE $SGMO $TSHA cantor is the world's worst at very thing they touch , including but not limited to 1) how. Tariffs are legally initiated, lol 2) who pays for Lutnick’s illegal idea of tariffs No more needed to be said …Low , scum , investment house
1 · Reply
Latest News on TSHA
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 29, 2025, 1:06 PM EDT - 5 months ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?


Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Jan 27, 2025, 7:53 PM EST - 9 months ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome


What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?


Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'

Nov 3, 2023, 7:41 PM EDT - 2 years ago

Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'


Dark_Horse_Investments
Dark_Horse_Investments Oct. 27 at 6:57 PM
$TSHA choppy seesaw reaction the last ~two weeks ... Do we think this will end the year above $6 ? THX & good luck
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 26 at 5:16 PM
Nice to see RA Capital long 7m shares of $RNA. A cool $1/2b that needs re-investing tomorrow thanks to $NVS. They are some lucky investors - or . *are they the actual people who facilitate value creation*? https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline $IFRX $CDTX $TSHA
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 5:43 PM
Raymond James has updated their rating for Taysha Gene Therapies ( $TSHA ) to Strong Buy with a price target of 13.
1 · Reply
King_of_Bio
King_of_Bio Oct. 21 at 3:22 PM
$TSHA She's headed for the next leg up!
1 · Reply
DaBullRunner
DaBullRunner Oct. 20 at 10:40 PM
$ABAT what a comeback 💪🤑💰💰💰💰 RVP is my next one 🚨🚨🚨 Here’s why👇 $BYND $TSHA what an AH
0 · Reply
Quantumup
Quantumup Oct. 20 at 8:30 PM
Raymond James🏁 $TSHA Strong Buy/$13 $NGNE $ACAD $ALPMY Raymond James said: Initiating coverage of Taysha Gene Therapies (TSHA) with a Strong Buy rating and $13 price target, as we think TSHA is well-positioned for success in its pivotal trial for patients with Rett syndrome (RTT), based on strong results from Part A of the Phase 1/2 REVEAL trial and constructive feedback from FDA. Raymond James added:
0 · Reply
biotech
biotech Oct. 20 at 5:37 PM
1 · Reply
quickaspeter
quickaspeter Oct. 19 at 11:30 PM
$TSHA “Taysha Gene Therapies regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.” https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-valuation-perspectives-after-rega
0 · Reply
Mighty_Fire_5931
Mighty_Fire_5931 Oct. 19 at 10:11 PM
$TSHA Perfect bounce off support, adding here
0 · Reply
Dkll303
Dkll303 Oct. 18 at 1:04 PM
$QURE $SGMO $TSHA cantor is the world's worst at very thing they touch , including but not limited to 1) how. Tariffs are legally initiated, lol 2) who pays for Lutnick’s illegal idea of tariffs No more needed to be said …Low , scum , investment house
1 · Reply
biotech
biotech Oct. 18 at 11:56 AM
$SGMO Cantor says $TSHA roughly 1/3 $QURE market cap despite both: latestage derisking data regulatory support both sizable rare disease markets $QURE ~5-6K patients vs ~10K patients for $TSHA i say same goes for $SGMO but with 25K+ Fabry patients $SGMO marketcap 190M or 1/17 $QURE
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 17 at 9:49 PM
seems $NGNE was more dependent on the Astellas exclusive rights to acquire RETT asset (company) from $TSHA than tsha was to hold price level As astellas exclusivity expired on ~ 09/30/25, as confirmed yesterday by TSHA sec filing, both companies traded down today (logically TSHA was expected to face trading pressure) notwithstanding TSHA down -7% NGNE down -14.5% where is the fluff valuation ?
0 · Reply
warren5677
warren5677 Oct. 17 at 7:54 PM
$TSHA Close of $4.75 or better is what I was thinking all day. It's going to be close.
0 · Reply
biotech
biotech Oct. 17 at 3:54 PM
$SGMO $TSHA #Astellas
1 · Reply
JFais
JFais Oct. 17 at 2:23 PM
Gene therapy players in Rett $NGNE $TSHA at top of losers scan today
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 11:58 AM
Chardan Capital updates rating for Taysha Gene Therapies ( $TSHA ) to Buy, target set at 12.
0 · Reply
biotech
biotech Oct. 17 at 10:44 AM
#Astellas not buying $TSHA re but $SGMO ?
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 10:37 AM
Needham has adjusted their stance on Taysha Gene Therapies ( $TSHA ), setting the rating to Buy with a target price of 10.
0 · Reply
biotech
biotech Oct. 17 at 7:47 AM
$SGMO #Astellas returns right to $TSHA #RETT Syndrome programe ... (intrathecally delivered AAV9) re $SGMO STAC-BBB #RETT $TSHA - Astellas + $SGMO RETT Wedbush: STAC-BBB Neuro Capsids Wedbush $SGMO STAC-BBB Capsid Could Attract Attention from Potential Partners Huntington's, Parkinson's, #Rett #Syndrome, Friedrich's Ataxia, cerebellar ataxias, prion disease, Dravet Syndrome, Alzheimer's, MS, frontotemporal dementia, ALS and progressive supranuclear palsy
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 16 at 9:13 PM
$TSHA BREAKING NEWS "Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome" * sec filing link below Astellas optionality to acquire Rett program (or perhaps company) is off the table for now... Good for TSHA all around to regain rights for a therapy that works. Will simplify negotiations with potential suitors in the future. ... hummm, is something in the works? https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319512492&type=PDF&symbol=TSHA&cdn=b55420705119565484baa3f482704454&companyName=Taysha+Gene+Therapies+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2025-10-16
1 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 15 at 6:06 PM
$TSHA Unscientific Poll Here: what is the max peak value of this stock in the next 24 Months: a) $18.5 -> takeout @ $5 Billion b) $24.1 -> max valuation in period, $6.5 Billion c) $12.9 -> early takeout @ $3.5 Billion d) $8.0 -> marred by delays & fda issues e) something different Kindly offer some substantive thoughts, not just like/hearts (all good too but please share) Best to all longs here on this relatively under the radar ride...
2 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Oct. 15 at 5:57 PM
$TSHA Xpekt big institutional buys when the next 13-f are filed...
0 · Reply